BY EDISON JOSEPH GONZALES
Nasdaq-listed ALPS Group Inc. is planning a Philippine wellness venture focused on helping people understand their health earlier through preventive assessments, personalized guidance and biotechnology-backed services.
The Malaysia-based biotechnology and life sciences company is targeting an opening in the second quarter of 2027 for a concept combining preventive medicine, advanced diagnostics, regenerative healthcare, recovery technologies, hospitality and design.
ALPS is working with Filipino collaborators to explore the concept, including IDr. Paolo Castro, founder and principal designer of Bespoke 88 + Branding and former national president of the Philippine Institute of Interior Designers, and Dr. Jacob Del Rosario, chief executive officer of CJ Medical Innovations. Their specific roles in the venture have not been detailed.
ALPS Chief Operating Officer Amanda Low said most healthcare today, whether in hospitals, clinics or wellness resorts, is organized around treating problems once they appear.
“Our focus is the step before that: helping people understand their health earlier and manage it consistently, with assessments and personalized guidance brought together in one coordinated experience rather than scattered across providers,” Low said.
The specific services, pricing and commercial model remain under development. ALPS has not disclosed the planned facility’s location, investment cost, projected revenue or the financial arrangements for the Philippine venture.
The company is targeting individuals who want to take a more proactive approach to their health through assessments, personalized insights and ongoing guidance rather than one-off treatment. It also intends to make preventive health accessible to a broader range of people, although its pricing tiers and service offerings have yet to be determined.
“Our intention over time is to make preventive health more accessible to a broad range of people, not only a narrow segment, though exactly how the tiers and offerings are structured is still being worked out,” Low said.
ALPS has yet to specify which services will generate revenue or explain how it intends to make the Philippine operation profitable. Low said the venture remained in development and that its financial details would be disclosed through appropriate channels, including securities filings, as plans take shape.
The venture’s potential market will depend on consumer purchasing power, demand for specific services, regulatory requirements and the availability of suitable healthcare infrastructure, Low said. ALPS has not provided an estimate of the addressable market.
The company is not positioning the proposed venture primarily as a bid to attract international medical tourists, despite established medical tourism markets in Singapore, Thailand and Malaysia.
“Those are strong, established destinations, and we respect what they’ve built. Our starting point is different: we’re focused on serving people in the Philippines rather than on competing to attract medical tourists. We believe a model built around precision and preventive healthcare management and ongoing, personalized guidance that are close to where people live can be genuinely valuable here. Whether that becomes a draw beyond the local market is something we’d rather demonstrate than predict,” Low said.
The company’s announcement, however, describes the collaboration as an effort to position the Philippines among Asia’s emerging destinations for science-backed wellness and cites the country’s appeal as a medical tourism destination.
The proposed concept would combine clinical assessments and health services with hospitality and design to shape the customer experience.
“It takes all these elements to come together and create an experience, not just the clinical assessment, but how approachable, personal and well-designed the experience around it feels. We will want to make people feel comfortable, seen and understood,” Low said.
Founded by Datuk Seri Dr. Tham Seng Kong, ALPS says it has capabilities spanning genomics, molecular diagnostics, messenger RNA technologies, cellular therapies and regenerative medicine.
The company’s planned focus on longevity and regenerative healthcare also raises questions about the scientific evidence behind interventions and the benefits customers can reasonably expect.
Low said ALPS prioritizes patient safety, scientific integrity and responsible clinical practice. The company aims to align its services with applicable regulatory requirements, relevant quality standards and available scientific evidence. Treatment decisions would be subject to appropriate clinical assessments, consideration of potential risks and benefits, and informed consent, as applicable.
“ALPS recognises that longevity is an evolving field and that no responsible healthcare provider should promise a specific lifespan extension or guaranteed clinical outcome,” Low said.
Results would depend on the services received, individual health circumstances and the scientific evidence supporting each intervention, she said. ALPS said it would rely on transparency, responsible clinical practice and continuing evaluation rather than longevity claims that cannot be substantiated.
The company has also yet to disclose how much it plans to invest in the Philippine venture or how financial risks and potential returns will be allocated. Low said execution would depend on market conditions, regulatory considerations, funding, operational readiness and customer adoption.
The planned expansion comes as ALPS faces financial challenges. The company reported revenue of $4.86 million for the fiscal year ended March 31, 2026, up 44 percent from the previous year, but posted a net loss of about $2.09 million. Its annual report also disclosed a material uncertainty that could cast significant doubt on its ability to continue as a going concern, citing its financial position and reliance on continued financial support from a director.
ALPS disclosed in May that it had received a Nasdaq notice over its failure to meet the exchange’s minimum $1 share-price requirement. The notice gave the company until Nov. 11, 2026, to regain compliance and did not immediately affect the listing or trading of its shares.
The global wellness economy reached $6.3 trillion in 2023, according to the Global Wellness Institute. Philippine total health expenditure reached P1.44 trillion that year, according to the Philippine Statistics Authority. The figures illustrate the scale of the broader wellness and health sectors but do not establish the addressable market for ALPS’ proposed venture.
Source: Bilyonaryo News Channel — Edison Joseph Gonzales, October 15, 2026.